Clinical Trials Logo
  1. Home
  2. Coronavirus Infections
  3. NCT05276388
  4. Details
NCT05276388 Clinical Trial

Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19)

Coronavirus Infections Clinical Trial

Official title:
Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-Cov-2 Infection (COVID-BioVac)

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT05276388
Other study ID # COVID BioVAC
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date March 31, 2023

Study information
Verified date March 2022
Source IRCCS San Raffaele
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Establishment of a biological bank of subjects vaccinated against SARS-Cov-2 infection (COVID-BioVac)

Description:

The purpose of the COVID-BioVac study is to establish a biobank of biological samples from subjects who have received the anti-SARS-CoV-2 vaccine, with the ultimate aim (following approval by the EC of specific substudies) to study and characterize the antiviral immune response generated following anti-SARS-CoV-2 vaccination. To this end, the COVID-BioVac Biobank will be officially established for the collection and storage of human biological material, non-profit, to support research activities aimed at advancing scientific knowledge, including in the genetic field, on the immune response. vaccination-induced anti-SARS-CoV-2.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 1100
Est. completion date March 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Who have vaccinated for SARS-CoV-2 with Pfizer-BioNTech vaccine or others - Signing of informed consent from January to March 2021 Exclusion Criteria: - none

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• biological bank
biological bank of subjects vaccinated against SARS-CoV-2 infection

Locations
Country Name City State
Italy IRCCS Ospedale San Raffaele Milan Milano

Sponsors (1)
Lead Sponsor Collaborator
IRCCS San Raffaele

Country where clinical trial is conducted

Italy, 

Outcome
Type Measure Description Time frame Safety issue
Primary COVID-19 vaccines response Create a Biobank to evaluate the immunogenicity of COVID-19 vaccines in terms of antibody titers from Day 1 of first vaccination up to 1 years after the last vaccination
See also
  Status Clinical Trial Phase
Completed NCT04553575 - CoViD-19 Patient in Reims University Hospital in March to April 2020
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Active, not recruiting NCT05548439 - Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a Phase 1
Completed NCT05046548 - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 Phase 1/Phase 2
Active, not recruiting NCT05726084 - Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older Phase 2/Phase 3
Recruiting NCT05069129 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 1/Phase 2
Enrolling by invitation NCT05054075 - Protocol Design for Evaluating the Immunity of Bivalve Fluids From Anodonta Cygnea in SARS and COVID-19 Phase 2
Recruiting NCT05599516 - Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial Phase 3
Completed NCT05047900 - The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community N/A
Completed NCT04420286 - Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France
Completed NCT04424355 - Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection.
Completed NCT05083039 - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Terminated NCT04409873 - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) Phase 2
Enrolling by invitation NCT04327349 - Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial N/A
Completed NCT04321278 - Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) Phase 3
Recruiting NCT04327570 - In-depth Immunological Investigation of COVID-19.
Completed NCT04326309 - Audio Data Collection for Identification and Classification of Coughing
Recruiting NCT04322344 - Escin in Patients With Covid-19 Infection Phase 2/Phase 3
Completed NCT04323592 - Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
Completed NCT04328129 - Household Transmission Investigation Study for COVID-19 in Tropical Regions N/A